Navigation Links
Texas Woman Alleges Actos Caused her Bladder Cancer, Parker Waichman LLP Files Lawsuit on Victim’s Behalf
Date:5/6/2013

New York, New York (PRWEB) May 06, 2013

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of a Texas woman who developed bladder cancer, allegedly due to using Actos. The suit was filed on April 2, 2013, in the U.S. District Court for the Western District of Louisiana (Case No. 6:13-cv-0704), where it is one of thousands of cases pending in the Actos multidistrict litigation (In Re: Actos (Pioglitazone) Products Liability Litigation, MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiffs’ Steering Committee in the litigation. Takeda Pharmaceuticals, America; Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc.; Takeda Pharmaceutical Company Limited; and Eli Lilly and Company have been named as Defendants.

According to the Complaint, the Plaintiff began taking Actos around May 2000 and stopped taking the drug around June 2001, about which time she had developed bladder cancer, allegedly as a result of taking Actos. The Defendants allegedly knew that taking the diabetes drug could lead to an increased risk of bladder cancer, but failed to disclose this information to the Plaintiff, her doctor and other consumers. She is seeking damages for permanent injuries, emotional distress, economic loss due to medical expenses and living-related expenses due to a new lifestyle.

Thousands of Actos lawsuits have been filed in state and federal courts across the country, according to an April 16, 2013, Bloomberg report. Actos is a Type 2 diabetes medication that was approved by the U.S. Food and Drug Administration i
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related medicine news :

1. Texas Veterinary Cancer Registry Expands Nationally
2. North Texas Coaches Announce May 3rd Rick Carson Workshop and Luncheon
3. Skechers Injury Lawsuit Filed on Behalf of a Texas Woman Who Sustained a Number of Serious Injuries Allegedly Due to Design of Skechers Shape-Ups, By Wright & Schulte
4. First Choice Emergency Room Hosts Event in Cypress, Texas to Celebrate the Local Community
5. Dr. Buckingham of Buckingham Center for Facial Plastic Surgery Re-Elected as Texas Medical Association Delegate
6. Texas Truck Accident Lawyers Praise New Safety Technology
7. WINFertility Treatment Program Expands to Central/Southern Texas. Program Makes IVF Treatment More Affordable for Patients Without Infertility Insurance Coverage.
8. North Texas Coaches Announce April 12 Monthly Luncheon Program and Workshop
9. Fresh Healthy Vending Expands to Northern Texas Area to Provide Healthier Options in Vending Machines
10. Ronica N. Holcombe, DPM, of North Texas Foot & Ankle Now Certified to Perform Innovative Surgery for Treatment of Diabetic Neuropathy
11. Texas physician breaks ground in robotic cervical surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... AZ (PRWEB) , ... September 05, 2015 , ... ... Artists from China for an exclusive, one-night exhibition of their work at Paradise Valley ... exhibit on Friday, September 18, from 6-9 pm. The artists will be on hand ...
(Date:9/4/2015)... CA (PRWEB) , ... September 04, 2015 , ... According ... has been developed that changes color when subjected to an impact force that is ... could be implemented in helmets or other sporting equipment so that coaches or officials ...
(Date:9/4/2015)... ... 2015 , ... On the heels of highly successful events ... its annual health tech innovation program. Now featuring a two-phase health tech competition ... cash and prizes to advance their technologies toward commercialization, the newly expanded program ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mile High Connects today releases “First ... lack of funding for sidewalks, bike paths, and other vital supports severely limit access ... region spends billions of dollars to expand public transit, there’s very little support for ...
(Date:9/4/2015)... ... 04, 2015 , ... The Providence Fertility Center will host a Fertility Cocktail ... egg freezing. , Date and Time: October 8, 2015 at Waterman Grille restaurant and ... informative event will discuss the basics of female fertility and egg freezing, and offer ...
Breaking Medicine News(10 mins):Health News:Paradise Valley Community College Announces Master Ceramic Artists & Exhibit 2Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Missed Connections in Metro Denver Transit 2Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2
... In an effort to reach out to,wounded soldiers, Retired ... a series of uplifting and rejuvenating weekend,retreats -- offered ... trips,focus on rest and relaxation for soldiers hurt in ... combat with Islamic Terrorists,these brave men and women are ...
... A new medication that researchers had hoped ... stenting has turned in a disappointing performance in ... that was used to deliver the drug is ... was expected to reduce arterial inflammation and, therefore, ...
... Percutaneous coronary intervention (PCI) may be a reasonable alternative ... left main coronary artery, according to a study that ... stents and bypass surgery were used to restore blood ... treated with stenting were more likely to need a ...
... - Response Biomedical,Corporation (TSX: RBM, OTCBB: RPBIF) reported ... net loss of $13,901,041 or ($0.12) per share,for ... Company announced,that as of December 31, 2007 it ... further discussion of the Company,s financial results for,the ...
... Pharmaceutical Holdings, Inc. (Amex: KUN ) ("China ... research, development, manufacture,and marketing of pharmaceutical, nutritional supplement ... ("PRC"), today announced it will,conduct a conference call ... 2008, to,discuss the Company,s financial results for the ...
... NMHC,s Stockholders Accept ... SXC,s ... -,SXC Health Solutions Corp. ("SXC") (Nasdaq: SXCI ; TSX: SXC) ... jointly announced,today that, pursuant to their previously announced merger agreement, SXC ...
Cached Medicine News:Health News:Healing Wounds and Hearts: Warrior Weekend Helps Soldiers Relax and Recover 2Health News:Investigational anti-restenosis drug pimecrolimus disappoints 2Health News:Investigational anti-restenosis drug pimecrolimus disappoints 3Health News:Study finds support for PCI in unprotected left main disease 2Health News:Study finds support for PCI in unprotected left main disease 3Health News:Response Biomedical Corporation Reports 2007 Financial Results 2Health News:Response Biomedical Corporation Reports 2007 Financial Results 3Health News:Response Biomedical Corporation Reports 2007 Financial Results 4Health News:Response Biomedical Corporation Reports 2007 Financial Results 5Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 2Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 3Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 4Health News:SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc. 5
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: